Gene Editing Technology Holds Promise to Eradicate HIV in the Future
- Japan Second Round of Nuclear Contaminated Water Discharge Set to Commence
- Johns Hopkins University: Early Plasma Therapy Reduces Long COVID Risk
- Ketogenic Diet Linked to Heart Diseases and Cancers
- TROP2 ADC for Breast Cancer Succeeded In Phase III Clinical Trials
- Lead Poisoning’s More Serious Impacts on Health and IQ
- Startling Link Between Alcohol and Alzheimer’s Disease
CRISPR-Cas9 Gene Editing Technology EBT-001 Holds Promise to Eradicate HIV in the Future
- Nearly 300 People Food Poisoning in Japanese 130-Year Restaurant
- FDA’s First Potential TIL Therapy Review Delayed: How to Understand FDA’s “Resource Constraints”?
- A Chinese Doctor Accused of Accepting Bribes Totaling US$166 Million
- Nuclear contaminated water: Japanese government paid bribes and corrected the IAEA report
- Top 20 Companies of Instruments and Medical Equipment In The World
- The first DMD gene therapy SRP-9001 may cost 4 million US dollars
- How long can the patient live after heart stent surgery?
CRISPR-Cas9 Gene Editing Technology EBT-001 Holds Promise to Eradicate HIV in the Future
August 18 – Scientists from Temple University’s Lewis Katz School of Medicine in the United States have recently reported that the CRISPR-Cas9 gene editing technology known as EBT-001 has the potential to safely and effectively remove SIV (Simian Immunodeficiency Virus) from the genomes of non-human primates.
This pre-clinical research represents a significant step forward in the pursuit of HIV therapy for humans, with the related paper published online in the “Gene Therapy” journal.
The research team, including Dr. Kamel Khalili, Dr. Tricia Burdo, and HIV researchers from Temple University, conducted experiments with EBT-001 in rhesus macaques, a tool specifically designed to target the SIV pre-viral DNA.
The findings demonstrate that EBT-001 efficiently eliminated SIV, which had been dormant in the viral reservoirs within the host’s DNA, with no off-target effects observed in the animals.
This novel technology aims to permanently inactivate the virus within large animal model tissues using a one-time injection treatment method, and the safety of this approach has been confirmed through these pre-clinical trials in non-human primates.
The team packaged the SIV-specific CRISPR-Cas9 gene editing construct, EBT-001, into an adeno-associated virus 9 (AAV9) vector, which can be delivered into the bodies of SIV-infected animals through intravenous injection.
This achievement lays the foundation for the ongoing EBT-101 clinical trials, marking not only a significant milestone in HIV virus research but also advancing the development of multiple gene editing therapies for other infectious diseases like herpes simplex virus and hepatitis B.
(source:internet, reference only)
Disclaimer of medicaltrend.org
